In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Clinical outcome of the 2nd generation cryoballoon for pulmonary vein isolation in patients with persistent atrial fibrillation - A sub-study of the randomized trial evaluating single versus dual cryo

Session Poster session 3

Speaker Victoria Jansson

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Catheter Ablation
  • Session type : Poster Session
  • FP Number : P1471

Authors : D Mortsell (Uppsala,SE), V Jansson (Uppsala,SE), H Malmborg (Uppsala,SE), S Lonnerholm (Uppsala,SE), C Blomstrom Lundqvist (Uppsala,SE)


D Mortsell1 , V Jansson1 , H Malmborg1 , S Lonnerholm1 , C Blomstrom Lundqvist1 , 1Uppsala University, Department of Medical Sciences - Uppsala - Sweden ,



The 2nd generation cryoballoon has been shown to be an efficient technique for pulmonary vein isolation (PVI) for the maintenance of sinus rhythm and improved quality of life in patients with paroxysmal atrial fibrillation (PAF). Studies on persistent atrial fibrillation (PersAF), however, are lacking and and have not assessed atrial fibrillation (AF) symptoms or quality of life, improvement of which is the primary goal of the ablation procedure.


To assess the efficacy of the 2nd generation Cryoballoon for PVI in patients with PersAF, and to compare it to patients with PAF.


The outcome (arrhythmia recurrence at 12 months) was prospectively assessed in patients with PersAF(n=77) and compared to that in patients with PAF(n=62), who underwent PVI within a randomized trial evaluating single versus dual applications with the 2nd generation cryoballoon. Other endpoints included symptoms of AF, quality of life, procedure related characteristics, redo ablation rates and adverse events. Variables predicting recurrences were studied including all patients.


Freedom from arrhythmia recurrence was 64.9% after a single ablation and 68.8% after one or more procedures, which was significantly lower compared to PAF patients; 82.2% (p=0.029) and 83.9% (p=0.048) respectively, at 12 months (Figure 1). The improvements in EHRA score (-1.3±0.8, p<0.0001), AF symptom severity score (-5.0±4.2, p<0.0001) and EQ5D-5L global score (+10.4±20.3, p=0.0002) after ablation was significant compared to baseline. The re-ablation rate was 7/77 (9.1%) which did not differ from that in PAF patients, 9/62 (14.5%), p=0.42. Procedure duration, 104.8±37.4 versus 113±31.2 minutes (p=0.129), application time, 1605±659 versus 1521±557 seconds (p=0.103) and total adverse events after 12 months, 8/77 (10.4%) versus 5/62 (8.1%) (p=0.77) did not differ in PersAF versus PAF patients.


Both symptoms and QoL improved significantly in patients with PersAF after ablation. Freedom from AF was clinically significant but lower than in PAF patients. The cryoballoon seems an effective technique also in patients with persistent AF.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are